Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Breast Neoplasms 83 Neoplasm Metastasis 7 Neoplasms 6 Sarcoma 4 Squamous Cell Carcinoma of Head and Neck 3 Colorectal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Colonic Neoplasms 2 Carcinoma, Squamous Cell 2 Wilms Tumor 1 Urinary Bladder Neoplasms 1 Untreated Operable Early Breast Cancer 1 Triple Negative Breast Neoplasms 1 Testicular Neoplasms 1 Teratoma 1 Somatostatinoma 1 Solid Tumors 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Squamous Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1

Interventions

ribociclib 1 palbociclib 1 abemaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × DILI × palbociclib × Clear all

NCT06367335 2024-04-16

ETIC

University of Milano Bicocca

DILI

Data powered by HemOnc (CC BY 4.0) Colophon ⚡